الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - recombinant turkey herpesvirus, strain vhvt013-69, live - immunologicals for aves, domestic fowl, immunologicals - embryonated eggs; chicken - for active immunisation of chickens:to prevent mortality and to reduce clinical signs and lesions of infectious bursal disease.to reduce mortality, clinical signs and lesions of marek's disease.

نيوزيلاندا - الإنجليزية - Ministry for Primary Industries

virbac new zealand limited - recombinant feline omega interferon - recombinant feline omega interferon 10,000 thou iu/ml - immune stimulant

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

baxalta us inc. - antihemophilic factor, human recombinant (unii: p89dr4ny54) (antihemophilic factor, human recombinant - unii:p89dr4ny54) - antihemophilic factor, human recombinant 400 [iu] in 1 ml

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

cangene biopharma - coagulation factor ix recombinant human (unii: 382l14738l) (coagulation factor ix recombinant human - unii:382l14738l) - coagulation factor ix recombinant human 500 [iu] in 5 ml

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

guna spa - interleukin-12 human recombinant (unii: 02fxp10o2u) (interleukin-12 human recombinant - unii:02fxp10o2u) - interleukin-12 human recombinant 4 [hp_c] in 30 ml - interleukin-12   4c   anti-allergy immune support anti-allergy immune support take 15 minutes before meals.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

baxter healthcare corporation - hyaluronidase recombinant human (unii: 743quy4vd8) (hyaluronidase recombinant human - unii:743quy4vd8) - hyaluronidase recombinant human 150 [usp'u] in 1 ml

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nonacog alfa, quantity: 2000 iu - injection, powder for - excipient ingredients: glycine; sucrose; polysorbate 80; histidine - benefix is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings. benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii, vii and x), nor for the treatment of haemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin induced anti-coagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nonacog alfa, quantity: 1000 iu - injection, powder for - excipient ingredients: polysorbate 80; histidine; sucrose; glycine - benefix is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings. benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii, vii and x), nor for the treatment of haemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin induced anti-coagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nonacog alfa, quantity: 500 iu - injection, powder for - excipient ingredients: sucrose; histidine; polysorbate 80; glycine - benefix is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings. benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii, vii and x), nor for the treatment of haemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin induced anti-coagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nonacog alfa, quantity: 250 iu - injection, powder for - excipient ingredients: polysorbate 80; histidine; glycine; sucrose - benefix is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings. benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii, vii and x), nor for the treatment of haemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin induced anti-coagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.